Overview of Sotorasiib and Medication Instructions for Patients

Sotoracib, its trade name isLumakras, which was called AMG 510 when it was developed. It is a small molecule targeted therapy drug for the KRAS G12C gene mutation. This drug was carefully developed by Amgen and received accelerated approval from the U.S. Food and Drug Administration (FDA) in May 2021. It is specifically used to treat patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have undergone at least one previous systemic treatment and carry KRAS G12C mutations.

KRAS G12C mutations are quite common in non-small cell lung cancer, accounting for approximately 13% of mutations in this type of lung cancer. The innovation of sotorasibu is that it can specifically bind to the KRAS G12C protein and keep it in an inactive state, thereby effectively preventing the abnormal proliferation and spread of cancer cells. This breakthrough drug undoubtedly brings new treatment hope to patients with KRAS G12C mutant non-small cell lung cancer worldwide.

In order to ensure the safe and effective use of sotoraxib, the following detailed medication instructions are provided for patients:

1. Dosage and administration method

The recommended dose of sotoraxib is 960 mg taken orally once daily. Patients can choose to take it with or without food, but it is recommended to take it within the same time period every day to maintain stable blood concentration.

2. Strictly follow the doctor’s instructions when taking medication

Patients must use the medicine strictly according to the doctor's instructions and never adjust the dosage or stop the medicine on their own. If you have difficulty swallowing, follow the special instructions in the instructions, but remember not to chew, crush, or break the tablets.

3. Closely monitor side effects

Sotorasiib may cause a range of side effects, including diarrhea, musculoskeletal pain, nausea, fatigue, and hepatotoxicity. Patients should always pay attention to their body's reactions and report serious or persistent adverse reactions to their doctor immediately. In particular, serious side effects such as liver damage and interstitial lung disease (ILD) may require temporary or permanent discontinuation of the drug.

4. Pay attention to drug interactions

While taking sotoraxib, patients should avoid concurrent use of other medications that may affect drug metabolism or effects. If you are using other drugs, be sure to inform your doctor so that the doctor can evaluate and adjust the medication plan.

5. Adjust lifestyle to assist treatment

Maintaining healthy lifestyle habits is crucial to improving the effectiveness of treatment. Patients should pay attention to a balanced diet, moderate exercise and adequate sleep. At the same time, maintain communication with family, friends or professional psychological counselors and seek necessary psychological support to better cope with challenges during the treatment process.

To sum up, Sotorasibu is the world’s first anti-Anti-cancer drugs with KRAS G12C mutations have opened up new treatment avenues for patients with KRAS G12C mutated non-small cell lung cancer. However, patients must strictly abide by medical instructions during medication, closely monitor side effects, and adjust their lifestyle to assist with treatment effects.